CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended March 31, 2014.
Recent key corporate and clinical developments include:
•Reported March and April 2014 as new record months for patient enrollment in the Company’s Phase III head and neck cancer trial.
Help employers find you! Check out all the jobs and post your resume.
